Post-menopausal osteoporosis

Indication for Raloxifene

Population group: Suitable for women, only adults (18 years old or older)
Therapeutic intent: Curative procedure

Raloxifene is indicated for the treatment of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

For this indication, competent medicine agencies globally authorize below treatments:

60 mg once daily

Route of admnistration


Defined daily dose

60 - 60 mg

Dosage regimen

From 60 To 60 mg once every day

Detailed description

The recommended dose is 60 mg daily by oral administration, which may be taken at any time of the day without regard to meals. Due to the nature of this disease process, raloxifene is intended for long term use.

Generally calcium and vitamin D supplements are advised in women with a low dietary intake.

No dose adjustment is necessary for the elderly.

Active ingredient

As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues.

Read more about Raloxifene

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner